These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3930330)

  • 1. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial.
    Fagius J; Brattberg A; Jameson S; Berne C
    Diabetologia; 1985 Jun; 28(6):323-9. PubMed ID: 3930330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.
    Lewin IG; O'Brien IA; Morgan MH; Corrall RJ
    Diabetologia; 1984 Jun; 26(6):445-8. PubMed ID: 6432615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy.
    Jaspan JB; Herold K; Bartkus C
    Am J Med; 1985 Nov; 79(5A):24-37. PubMed ID: 3000176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.
    Jaspan JB; Towle VL; Maselli R; Herold K
    Metabolism; 1986 Apr; 35(4 Suppl 1):83-92. PubMed ID: 3083212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil.
    O'Hare JP; Morgan MH; Alden P; Chissel S; O'Brien IA; Corrall RJ
    Diabet Med; 1988 Sep; 5(6):537-42. PubMed ID: 2974776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function.
    Martyn CN; Reid W; Young RJ; Ewing DJ; Clarke BF
    Diabetes; 1987 Sep; 36(9):987-90. PubMed ID: 3111914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological inhibition of aldose reductase in human diabetic neuropathy.
    Jaspan J
    Drugs; 1986; 32 Suppl 2():23-9. PubMed ID: 2431859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of an aldose reductase inhibitor (Sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study.
    Christensen JE; Varnek L; Gregersen G
    Acta Neurol Scand; 1985 Feb; 71(2):164-7. PubMed ID: 3920861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.
    Sima AA; Bril V; Nathaniel V; McEwen TA; Brown MB; Lattimer SA; Greene DA
    N Engl J Med; 1988 Sep; 319(9):548-55. PubMed ID: 3136331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials of sorbinil on nerve function.
    Pfeifer MA
    Metabolism; 1986 Apr; 35(4 Suppl 1):78-82. PubMed ID: 3083211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy.
    Young RJ; Ewing DJ; Clarke BF
    Diabetes; 1983 Oct; 32(10):938-42. PubMed ID: 6225686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment.
    Guy RJ; Gilbey SG; Sheehy M; Asselman P; Watkins PJ
    Diabetologia; 1988 Apr; 31(4):214-20. PubMed ID: 3290018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
    Sima AA; Prashar A; Nathaniel V; Bril V; Werb MR; Greene DA
    Diabet Med; 1993 Mar; 10(2):115-21. PubMed ID: 8458187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sorbinil retinopathy trial: neuropathy results. Sorbinil Retinopathy Trial Research Group.
    Neurology; 1993 Jun; 43(6):1141-9. PubMed ID: 8170559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.
    Fagius J; Jameson S
    J Neurol Neurosurg Psychiatry; 1981 Nov; 44(11):991-1001. PubMed ID: 6801211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in peripheral nerve function after one year of Sorbinil.
    Gieron MA; Malone JI; Lowitt S; Korthals JK
    Neuroreport; 1991 Jun; 2(6):348-50. PubMed ID: 1655107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function.
    Jaspan J; Maselli R; Herold K; Bartkus C
    Lancet; 1983 Oct; 2(8353):758-62. PubMed ID: 6137601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy.
    Jennings PE; Nightingale S; Le Guen C; Lawson N; Williamson JR; Hoffman P; Barnett AH
    Diabet Med; 1990 Jan; 7(1):63-8. PubMed ID: 2137066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.
    Tomlinson DR; Moriarty RJ; Mayer JH
    Diabetes; 1984 May; 33(5):470-6. PubMed ID: 6202576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
    Hotta N; Toyota T; Matsuoka K; Shigeta Y; Kikkawa R; Kaneko T; Takahashi A; Sugimura K; Koike Y; Ishii J; Sakamoto N;
    Diabetes Care; 2001 Oct; 24(10):1776-82. PubMed ID: 11574441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.